Combination of [ 177 Lu]Lu-PSMA-617 and [ 177 Lu] Lu-TBM in Prostate Cancer: A Comparative Study of Safety and Survival Outcomes (EANM 2026) - Sep 29, 2026 - Abstract #OP-641; Pres time: Oct 20, 2026; 09:45 AM - 11:15 AM; Location: Hall K; "The combination of [177Lu] Lu-PSMA-617 and [177Lu]Lu-DOTA-IBA does not significantly increase treatment-related toxicities. Compared with [177Lu] Lu-PSMA-617 monotherapy, the combination regimen may improve overall survival in patients with prostate cancer."
Clinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|